AIDS (Acquired Immune Deficiency Syndrome) blood purification therapeutic apparatus

Abstract

The invention discloses an AIDS (Acquired Immune Deficiency Syndrome) blood purification therapeutic apparatus, comprising a blood and blood serum separator capable of separating blood serum, single blood cell from multinucleated giant cells formed by inquilinous HIV (Human Immunodeficiency Virus) and comprising a purifier including an HIV antibody capable of being combined with the HIV, a CD4+T cell line and a hybridoma macrophage cell line. When blood flows through the separator, the multinucleated giant cells containing the HIV are filtered out; when the separated blood serum flows through the purifier, the HIV is adsorbed and cleaned by a purification agent; the purified blood serum and the single blood cell separated by the separator are converged and then are conveyed back to a body, so that the AIDS blood purification therapeutic aim of cleaning the HIV in and out of the blood cells is realized.

Description

technical field [0001] The invention relates to an AIDS blood purification treatment instrument, which is mainly used for removing HIV inside and outside blood cells of AIDS patients, so as to achieve the purpose of preventing, controlling and treating AIDS. Background technique [0002] HIV infection can stimulate the body to produce envelope protein (Gp120, Gp41) antibodies and core protein (P24) antibodies. Low levels of antiviral neutralizing antibodies were detected in the serum of HIV carriers and AIDS patients, among which the level of AIDS patients was the lowest, and that of HIV carriers was the highest, indicating that the antibodies have a protective effect in the body. However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role. In the stage of latent infection, HIV provir...

AI Technical Summary

Problems solved by technology

However, the antibody cannot contact the virus remaining in the mononuclear macrophage, and the HIV envelope protein is prone to antigenic variation, and the original antibody loses its effect, so that the neutralizing antibody cannot play its due role

During the latent infection stage, the HIV provirus is integrated into the host cell genome, so HIV will not be recognized by the immune system, so it cannot be eliminated by autoimmunity alone

Another very important reason should be that, based on the mechanism of antibody killing and clearing antigens, it is speculated that after the immune antibody binds to the antigen, it will produce an immune effect, or it will mediate the ADCC effect to dissolve the cellular antigen by activating complement, but HIV does not Cellular antigens; either attract phagocytes to phagocytize and clear antigens through chemotaxis, but HIV is protected and proliferated in phagocytes instead; or antibodies combine with antigens to neutralize and make them lose their infectivity, but the structure of HIV antigens is variable , often making it difficult for antibodies to recognize

[0003] Judging from the current AIDS treatment methods that have been used clinically, the effect is not so ideal: (1) HIV reverse transcriptase inhibitors: can only prevent the infection of susceptible cells that have not been infected with HIV, and have no therapeutic effect on infected cells, and are toxic There are many side effects, including mitochondrial toxicity, myelosuppression, erythrocytic anemia, neutropenia and thrombocytopenia, pancreatitis, and the generation of cross-drug resistance. Drug-resistant variants, resulting in decreased clinical efficacy or failure

(2) HIV protease inhibitors: prone to drug-induced liver injury, lipid metabolism disorders and other side effects and drug resistance

(4) Inhibiting HIV virus entry inhibitors: including blocking the binding of gp120 to CD4, blocking the binding of HIV to coreceptors, acting on gp41 membrane subunits, and acting on CC chemokine receptor 5 (CCR5) on the surface of T lymphocytes to block HIV from entering host cells, but has side effects on the liver and heart

(6) HIV vaccine treatment: Due to the particularity of HIV, such as innate immunity is not enough to resist HIV and its targeted destruction of the immune system, and the virus mutates rapidly, so far no truly safe and effective vaccine has been developed

(7) Gene therapy: HIV gene therapy research has never stopped, including antisense technology, RNA decoy, RNA interference, intracellular antibodies, dominant negative mutants, suicide genes, etc., but gene therapy that has entered phase II clinical trials hardly

[0007] In short, various drugs and biological products cannot effectively kill HIV in the body, and they are expensive and have severe side effects. So far, there is no effective method for the treatment of AIDS, which has become a worldwide problem that cannot be overcome for a long time.

Images